Claims for Patent: 11,173,118
✉ Email this page to a colleague
Summary for Patent: 11,173,118
| Title: | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
| Abstract: | Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy. |
| Inventor(s): | Ottoboni; Thomas B. (Belmont, CA), Han; Han (Mountain View, CA) |
| Assignee: | Heron Therapeutics, Inc. (San Diego, CA) |
| Application Number: | 16/820,311 |
| Patent Claims: |
1. An injectable pharmaceutical emulsion comprising: a neurokinase-1 (NK-1) receptor antagonist; an emulsifier; an oil; a co-surfactant; and an aqueous phase, wherein
the ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt %).
2. The emulsion according to claim 1, wherein the ratio of the oil to the NK-1 receptor antagonist ranges from about 5:1 to 15:1 (wt/wt %). 3. The emulsion according to claim 1, wherein the ratio of the oil to the NK-1 receptor antagonist ranges from about 10:1 to 15:1 (wt/wt %). 4. The emulsion according to claim 1, wherein the aqueous phase comprises water and a tonicity agent. 5. The emulsion according to claim 4, wherein the aqueous phase further comprises a pH modifying agent. 6. The emulsion according to claim 1, wherein the ratio of emulsifier to oil ranges from about 1:1 to 3:1 (wt/wt %). 7. The emulsion according to claim 1, wherein the emulsifier is a phospholipid. 8. The emulsion according to claim 1, wherein the emulsifier is an egg lecithin. 9. The emulsion according to claim 1, further comprising dexamethasone sodium phosphate, wherein the dexamethasone sodium phosphate is present in the aqueous phase. 10. The emulsion according to claim 1, wherein the NK-1 receptor antagonist is selected from the group consisting of rolapitant, netupitant, ezlopitant, vestipitant, serlopitant, maropitant, casopitant, befetupitant, and orvepitant. 11. The emulsion according to claim 5, wherein the pH modifier is an oleate or a salt thereof. 12. The emulsion according to claim 5, wherein the pH modifier is a buffer. 13. The emulsion according to claim 12, wherein the buffer is Tris buffer. 14. The emulsion according to claim 1, wherein the oil is soybean oil. 15. The emulsion according to claim 1, wherein the co-surfactant comprises an alcohol. 16. The emulsion according to claim 1, wherein the co-surfactant is ethanol. 17. The emulsion according to claim 16, wherein the ethanol is present in the emulsion at less than 10 wt/wt %. 18. The emulsion according to claim 1, wherein the NK-1 receptor antagonist is not aprepitant. |
